ELOX (Eloxx Pharmaceuticals) Change In Receivables: $2.36 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ELOX Eloxx Pharmaceuticals Inc ELOX
17 GF Score
Price $17.79
! 2 Warning Signs
View Full Analysis

What is Eloxx Pharmaceuticals Change In Receivables?

Eloxx Pharmaceuticals ELOX +1.25% 17 Change In Receivables is $2.36 Mil as of Dec. 2025. GuruFocus rates ELOX with a GF Score™ of 17/100. The stock has 2 warning signs investors should review.

Eloxx Pharmaceuticals's change in receivables for the quarter that ended in Dec. 2025 was $2.36 Mil. It means Eloxx Pharmaceuticals's Accounts Receivable declined by $2.36 Mil from Dec. 2024 to Dec. 2025 .

Eloxx Pharmaceuticals's change in receivables for the fiscal year that ended in Dec. 2025 was $2.36 Mil. It means Eloxx Pharmaceuticals's Accounts Receivable declined by $2.36 Mil from Dec. 2024 to Dec. 2025 .

Eloxx Pharmaceuticals's Accounts Receivable for the quarter that ended in Dec. 2025 was $0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Eloxx Pharmaceuticals's liquidation value for the six months ended in Dec. 2025 was $-12.39 Mil.

Eloxx Pharmaceuticals  (NAS:ELOX) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Eloxx Pharmaceuticals's Days Sales Outstanding for the quarter that ended in Dec. 2025 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=0/0*91
=

2. In Ben Graham's calculation of liquidation value, Eloxx Pharmaceuticals's accounts receivable are only considered to be worth 75% of book value:

Eloxx Pharmaceuticals's liquidation value for the quarter that ended in Dec. 2025 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=4.785-17.177+0.75 * 0+0.5 * 0
=-12.39

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eloxx Pharmaceuticals Change In Receivables Related Terms

Eloxx Pharmaceuticals Change In Receivables Historical Data

* Premium members only.

The historical data trend for Eloxx Pharmaceuticals's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eloxx Pharmaceuticals Change In Receivables Chart

Eloxx Pharmaceuticals Annual Data
Trend Jun16 Jun17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Change In Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 -2.36 2.36

Eloxx Pharmaceuticals Semi-Annual Data
Jun06 Jun07 Jun08 Jun09 Jun10 Jun11 Jun12 Jun13 Jun14 Jun15 Jun16 Jun17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 -2.36 2.36
ELOX
17GF Score
Eloxx Pharmaceuticals Inc ELOX
Change In Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Eloxx Pharmaceuticals Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2025 was $2.36 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Receivables →
What does a Change In Receivables of $2.36 Mil mean?
Eloxx Pharmaceuticals (ELOX) has a Change In Receivables of $2.36 Mil as of Dec. 2025. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Eloxx Pharmaceuticals and its competitors.
Is Eloxx Pharmaceuticals' Change In Receivables too high?
Eloxx Pharmaceuticals' current Change In Receivables is $2.36 Mil. Overall, Eloxx Pharmaceuticals has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Eloxx Pharmaceuticals' Change In Receivables compare to APLM and FLNA?
Eloxx Pharmaceuticals' Change In Receivables of $2.36 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Biotechnology company?
A good Change In Receivables depends on the Biotechnology industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Eloxx Pharmaceuticals and its competitors. Eloxx Pharmaceuticals's current Change In Receivables is $2.36 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eloxx Pharmaceuticals stock overvalued right now?
Eloxx Pharmaceuticals (ELOX) has a current Change In Receivables of $2.36 Mil. The current Change In Receivables is $2.36 Mil. Eloxx Pharmaceuticals' overall GF Score™ is 17/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For Eloxx Pharmaceuticals (ELOX), the current Change In Receivables is $2.36 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Eloxx Pharmaceuticals Business Description

Address 10 Court Street, P.O. Box 274, Arlington, MA, USA, 02476
Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in developing novel, small-molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations (NMs) to enable the production of full-length proteins. The exaluren, the company's investigational drug product for the treatment of rare kidney diseases, and, through the collaboration with Almirall, S.A. (Almirall), ZKN-013 for the treatment of rare skin diseases.
17GF Score

Get the complete analysis for ELOX

Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$17.79
Price